Rita Calado

Rita Calado

Auto-generated profile, based on publicly available information

Rita Calado

Department of Infectious Diseases, National Institute of Health, Avenida Padre Cruz, 1649-016, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Antiviral Therapy
Verified
Journal Article
Closed access
PBPedro Borrego
Pedro Borrego
RCRita Calado
Rita Calado
JMJosé M Marcelino
José M Marcelino
Inês BártoloInês Bártolo
Inês Bártolo
CRCheila Rocha
Cheila Rocha
Nuno TaveiraNuno Taveira
Nuno Taveira
Background: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. The 50% inhibitory concentration (IC 50 ), 90% inhibitory concentration (IC 90 ) and dose–response curve slopes were determined for each drug. Results: ENF and T-1249 were significantly less active on HIV-2 than on HIV-1 (211- and 2-fold, respectively). AMD3100 and TAK-779 inhibited HIV-2 and HIV-1 CXCR4 tropic (X4) and CCR5 tropic (R5) variants with similar IC 50 and IC 90 values. MVC, however, inhibited the replication of R5 HIV-2 variants with significantly higher IC 90 values (42.7 versus 9.7 nM; P<0.0001) and lower slope values (0.7 versus 1.3; P<0.0001) than HIV-1. HIV-2 R5 variants derived from AIDS patients were significantly less sensitive to MVC than variants from asymptomatic patients, this being inversely correlated with the absolute number of CD4 + T-cells. Conclusions: T-1249 is a potent inhibitor of HIV-2 replication indicating that new fusion inhibitors might be useful to treat HIV-2 infection. Coreceptor antagonists TAK-779 and AMD3100 are also potent inhibitors of HIV-2 replication. The reduced sensitivity of R5 variants to MVC, especially in severely immunodeficient patients, indicates that the treatment of HIV-2-infected patients with MVC might require higher dosages than those used in HIV-1 patients, and should be adjusted to the disease stage.

15 February 2011 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
RCRita Almeida Calado
Rita Almeida Calado
MRMaria Raquel Rocha
Maria Raquel Rocha
Ricardo ParreiraRicardo Parreira
Ricardo Parreira
JPJoao Piedade
Joao Piedade
TVTeresa Venenno
Teresa Venenno
AEAida Esteves
Aida Esteves

24 April 2013 in AIDS
Verified
Journal Article
Closed access
PBPedro Borrego
Pedro Borrego
RCRita Calado
Rita Calado
JMJosé M. Marcelino
José M. Marcelino
PPPatrícia Pereira
Patrícia Pereira
Alexandre QuintasAlexandre Quintas
Alexandre Quintas
Nuno TaveiraNuno Taveira
Nuno Taveira
To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences. HIV-2/simian immunodeficiency virus (SIV) ancestral transmembrane protein sequences were reconstructed and ancestral peptides were derived from the helical region 2 (HR2). The activity of one ancestral peptide (named P3) was examined against a panel of HIV-1 and HIV-2 primary isolates in TZM-bl cells and peripheral blood mononuclear cells and compared to T-20. Peptide secondary structure was analyzed by circular dichroism. Resistant viruses were selected and resistance mutations were identified by sequencing the env gene. P3 has 34 residues and overlaps the N-terminal pocket-binding region and heptad repeat core of HR2. In contrast to T-20, P3 forms a typical α-helical structure in solution, binds strongly to the transmembrane protein, and potently inhibits both HIV-2 (mean IC50, 63.8 nmol/l) and HIV-1 (11 nmol/l) infection, including T-20-resistant isolates. The N43K mutation in the HR1 region of HIV-1 leads to 120-fold resistance to P3 indicating that the HR1 region in transmembrane glycoprotein is the target of P3. No HIV-2-resistant mutations could be selected by P3 suggesting that the genetic barrier to resistance is higher in HIV-2 than in HIV-1. HIV-1-infected patients presented significantly lower P3-specific antibody reactivity compared to T-20. P3 is an HIV-2/SIV ancestral peptide with low antigenicity, high stability, and potent activity against both HIV-1, including variants resistant to T-20, and HIV-2. Similar evolutionary biology strategies should be explored to enhance the production of antiviral peptide drugs, microbicides, and vaccines.

1 August 2016 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
Inês BártoloInês Bártolo
Inês Bártolo
RCRita Calado
Rita Calado
PBPedro Borrego
Pedro Borrego
TLThomas Leitner
Thomas Leitner
Nuno TaveiraNuno Taveira
Nuno Taveira
Angola has an extremely diverse HIV-1 epidemic fueled in part by the frequent interchange of people with the Democratic Republic of Congo (RDC) and Republic of Congo (RC). Characterization of HIV-1 strains circulating in Angola should help to better understand the origin of HIV-1 subtypes and recombinant forms and their transmission dynamics. In this study we characterize the first near full-length HIV-1 genomic sequences from HIV-1 infected individuals from Angola. Samples were obtained in 1993 from three HIV-1 infected patients living in Cabinda, Angola. Near full-length genomic sequences were obtained from virus isolates. Maximum likelihood phylogenetic tree inference and analyses of potential recombination patterns were performed to evaluate the sequence classifications and origins. Phylogenetic and recombination analyses revealed that one virus was a pure subtype J, another mostly subtype J with a small uncertain region, and the final virus was classified as a H/U/CRF02_AG recombinant. Consistent with their epidemiological data, the subtype J sequences were more closely related to each other than to other J sequences previously published. Based on the env gene, taxa from Angola occur throughout the global subtype J phylogeny. HIV-1 subtypes J and H are present in Angola at low levels since at least 1993. Low transmission efficiency and/or high recombination potential may explain their limited epidemic success in Angola and worldwide. The high diversity of rare subtypes in Angola suggests that Angola was part of the early establishment of the HIV-1 pandemic.

24 October 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
CRCheila Rocha
Cheila Rocha
RCRita Calado
Rita Calado
PBPedro Borrego
Pedro Borrego
JMJosé Maria Marcelino
José Maria Marcelino
Inês BártoloInês Bártolo
Inês Bártolo
Nuno TaveiraNuno Taveira
Nuno Taveira
Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.Results: CD4+T cells decreased from about 50% to below 30% in both children in the first five years of infection and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable levels and CD4+T cells recovered to normal levels, which have been sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were related with rate of escape from the neutralizing antibodies.Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for a model in which Nabs play an important role in HIV-2 pathogenesis.

1 August 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TRTatu Rimpiläinen
Tatu Rimpiläinen
ANAlexandra Nunes
Alexandra Nunes
RCRita Calado
Rita Calado
Ana FernandesAna Fernandes
Ana Fernandes
JAJoana Andrade
Joana Andrade
NCNuno Candeias
Nuno Candeias